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Vitamin D Controls Murine and Human Plasmacytoid
Dendritic Cell Function
Nina Karthaus1, Annemiek B. van Spriel1, Maaike W.G. Looman1, Shuo Chen1, Lisanne M. Spilgies1,
Liesbet Lieben2,3, Geert Carmeliet2, Marleen Ansems1 and Gosse J. Adema1
Topical application of the vitamin D (VitD) analog calcipotriol is a highly effective standard treatment modality of
psoriatic skin lesions. However, the immune modulatory effects of the treatment are incompletely understood.
VitD is well known to induce tolerogenic responses in conventional dendritic cells (cDCs). Plasmacytoid DCs
(pDCs) comprise a specialized, naturally occurring DC subset known to be important in autoimmune diseases
including psoriasis. pDCs from the blood rapidly infiltrate psoriatic skin and are key to the initiation of the
immune-mediated pathogenesis of the disease. We now demonstrate that pDCs express various proteins of the
VitD receptor (VDR) pathway, including the VitD-metabolizing enzymes Cyp27B1 and Cyp24A1, and that VDR is
transcriptionally active in pDCs. Moreover, VitD impairs the capacity of murine and human pDCs to induce T-cell
proliferation and secretion of the T-helper 1 cytokine IFNg. The inhibitory effect of VitD is dependent on the
expression of the VDR in the DCs. This study demonstrates that VitD signaling can act as a natural inhibitory
mechanism on both cDCs and pDCs, which may instigate the development of VitD-based therapeutic
applications for psoriasis and other inflammatory skin diseases.
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INTRODUCTION
Psoriasis is a common autoimmune disease of the human skin,
affecting 2% of the population worldwide (Lebwohl, 2003).
Disease onset and chronic states are mediated by autoreactive
T cells and secretion of T-helper 1 (Th1) cytokines, which
induce the hyperproliferation of keratinocytes (Lebwohl, 2003;
Miteva, 2010). Recent studies have demonstrated that the
early pathogenesis of psoriasis is marked by the infiltration of
plasmacytoid dendritic cells (pDCs), a specialized subset of
DCs. pDCs are attracted to chemerin chemogradients in early
psoriatic lesions, they become activated through recognition
of self-DNA complexes, and subsequently exacerbate T-cell
activation, thereby driving disease development (Nestle et al.,
2005; Albanesi et al., 2009, 2010).
Current standard treatment modalities of psoriatic skin
plaques include the topical use of the vitamin D (VitD) analog
calcipotriol (Kragballe, 1995; Albanesi et al., 2010; Oquendo
et al., 2012). VitD refers to a group of metabolites that exert
their function through the VitD receptor (VDR). The active
metabolite calcitriol (1,25dihydroxyvitamin D3) is
metabolized from precursors during a multistep process
starting in the skin (White, 2012). Here, UVB induces the
conversion of 7-dehydrocholesterol into vitamin D3 (cholecal-
ciferol). Subsequently, cholecalciferol is hydroxylated in the
liver by the enzymes Cyp2R1 or Cyp27A1 to calcifediol
(25hydroxyvitamin D), the main circulating derivative of
VitD. Finally, calcifediol is hydroxylated by the enzyme
Cyp27B1 toward the active ligand calcitriol, in the kidneys.
Importantly, the metabolism of calcitriol is not restricted to
these specific tissues and can also take place in different cell
types expressing the enzymes, including conventional DCs
(cDCs; Gottfried et al., 2006). Although VitD therapy is very
effective in resolving skin plaques, the exact underlying
mechanisms of action are not yet completely understood.
In psoriatic lesions, VitD is known to inhibit the epidermic
hyperproliferation and promote differentiation of keratino-
cytes. Moreover, VitD has been shown to be a potent regulator
of immune responses in general and also in psoriatic skin
(Reichrath et al., 1997; Dam et al., 1999). The two main target
cells of VitD in the immune system are T cells and DCs.
Stimulation of T cells with VitD impairs their proliferation,
proinflammatory cytokine secretion (IFNg, IL-17), and
promotes development of Th2 and regulatory T cells (Daniel
et al., 2008; Jeffery et al., 2009). VitD-treated in vitro–
differentiated DCs express decreased levels of costimulatory
molecules and increased levels of inhibitory receptors.
Moreover, they secrete lower amounts of proinflammatory
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and higher amounts of anti-inflammatory cytokines (Berer
et al., 2000; Piemonti et al., 2000; Unger et al., 2009).
Consequently, VitD-treated DCs are less potent in their
induction of T-cell responses and induced the generation of
regulatory T cells. Few studies described a tolerogenic
response of VitD-treated naturally occurring blood DCs
(Penna et al., 2005, 2007; Sze´les et al., 2009). The data
from Penna et al. (2007) pointed toward a marked inhibitory
effect of VitD on cDCs, exclusively. They showed that
production of proinflammatory cytokines and upregulation of
costimulatory molecules by pDCs was unaffected after
treatment with VitD.
pDCs are the main producers of type I IFN; additionally,
when activated, they too are potent antigen-presenting cells
and inducers of T-cell responses (Tel et al., 2013a,b). The
precise effect of VitD on the antigen-presenting capacities of
pDCs has not been elucidated to date. Here, we show that
stimulation of murine and human pDCs with VitD before and
during maturation significantly impairs their T-cell stimulatory
capacities. The inhibitory effect of VitD was dependent on the
expression of the VDR. We conclude that VitD signaling acts
as a natural inhibitory mechanism on pDCs and cDCs.
RESULTS
Murine pDCs and cDCs respond to stimulation with calcitriol
and its precursor calcifediol
In a quantitative PCR-based screen for nuclear receptor
expression in DC subsets, we found expression of VDR and
its heterodimeric partner RXR in murine pDCs (Karthaus et al.,
2013). To corroborate these findings, we assessed the mRNA
levels of VDR in independent pDC and cDC samples freshly
isolated from bone marrow and spleen or derived from in vitro
progenitor cell cultures with Flt3L. These data confirmed that
in vitro–derived and lymphoid tissue–resident pDCs expressed
VDR mRNA levels (Figure 1a). In accordance with the mRNA
levels, also VDR protein was expressed in in vitro–cultured
pDCs (Figure 1b and c) and in pDCs in the bone marrow and
spleen (Figure 1c).
The transcriptional activity of VDR is affected by the
presence of the active ligand calcitriol, VitD-metabolizing
enzymes, and transcriptional co-regulators. We assessed the
mRNA levels of the VDR coactivator DRIP205 and the co-
inhibitor Hairless (Barletta et al., 2002; Chuma et al., 2012).
Both co-regulators were expressed at comparable levels in
Flt3L-derived pDCs and cDCs (Figure 2a). cDCs are known to
be able to actively synthesize the active VDR ligand calcitriol
from its precursors cholecalciferol and calcifediol, mediated
by the enzymes Cyp27A1 or Cyp2R1 and Cyp27B1, respec-
tively (Gottfried et al., 2006; Sigmundsdottir et al., 2007). Our
data show that both murine pDCs and cDCs express similar
levels of Cyp27A1 and Cyp2R1, as well as Cyp27B1
(Figure 2b). As pDCs and cDCs expressed co-regulators and
enzymes of the VitD pathway, we investigated whether VDR
was transcriptionally active and whether both subsets could
respond to the VitD precursor calcifediol. To this extent, pDCs
and cDCs were stimulated with calcifediol or calcitriol and
mRNA levels of the known VDR target genes VDR itself and
the enzyme Cyp24A1 were measured. pDCs and cDCs both
rapidly upregulated the expression of VDR 2 hours after
stimulation with calcitriol (Figure 2c). VDR mRNA was back
to baseline levels 16 hours after stimulation. Moreover, both
subsets also strongly upregulated VDR in response to calcife-
diol stimulation, indicating that calcifediol is processed into
active calcitriol and thus that the enzyme Cyp27B1 is active in
DCs. Expression of the target gene Cyp24A1 was induced
16 hours after stimulation with calcitriol, albeit at low levels
(Figure 2d). Calcifediol alone induced very low expression of
Cyp24A1 in pDCs only. Moreover, both pDCs and cDCs
responded to stimulation with the clinical VitD analog
calcipotriol (Supplementary Figure 1 online).
Taken together, these data show that both pDCs and cDCs
express transcriptionally active VDR protein and respond to
stimulation with the VitD precursor calcifediol and the active
VDR ligand calcitriol.
VitD impairs the T-cell stimulatory capacities of murine pDCs
VitD is part of the standard treatment of psoriatic skin lesions,
and different studies suggest that VitD therapy modulates the
immune response in skin plaques. As pDCs are implicated in
the initiation of psoriatic pathogenesis, we investigated the
T-cell stimulatory capacities of VitD-stimulated pDCs. DCs
were pre-treated with calcitriol and calcifediol and subse-
quently stimulated with CpG. After stimulation, DCs were
added to an allogeneic mixed leukocyte reaction. cDCs are
known to be impaired by VitD, and as expected VitD-
stimulated cDCs were much less potent in the induction of
T-cell proliferation compared with vehicle-treated cells
(Figure 3a). Intriguingly, also pDCs showed a remarkably
decreased T-cell–activating capacity when treated with VDR
ligands (Figure 3b). The inhibitory effect of VDR ligand
stimulation was most pronounced in unstimulated DCs com-
pared with CpG-stimulated cells in both pDCs and cDCs and
essentially absent when DCs were matured with the potent
Toll-like receptor ligand R848 (Supplementary Figure 2a
online). VDR-deficient (VDR / ) pDCs and cDCs were
generally slightly less effective T-cell stimulators compared
with wild-type DCs. However, upon stimulation with the VDR
ligands, VDR / DCs were not impaired in their T-cell–
activating potential, indeed demonstrating that the inhibitory
effect of VitD was dependent on the presence of VDR in DCs
(Figure 3).
Psoriasis is a Th1-driven disease; therefore, we next assessed
the secretion of cytokines in the allogeneic mixed leukocyte
reaction. In line with the impaired proliferation, also levels of
the Th1 cytokine IFNg were significantly decreased when
pDCs and cDCs were pre-treated with VDR ligands (Figure 4).
Moreover, inhibition of IFNg production was more prominent
in unstimulated pDCs compared with the CpG-stimulated
cells. Robust stimulation of pDCs and cDCs with R848 led to
small but significant impairment of IFNg secretion
(Supplementary Figure 2b online). Importantly, VDR /
DCs were not hampered in their capacity to induce IFNg in
T cells when stimulated with VDR ligands, confirming that the
inhibitory effect of VitD is dependent on VDR expression
(Figure 4). Furthermore, the secretion of IL5, IL10, and IL17
was not changed significantly between vehicle and calcitriol/
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calcifediol treatment (data not shown), indicating that VDR
stimulation did not alter T-cell skewing in this setting.
In conclusion, stimulation of the VDR inhibits the T-cell
stimulatory capacity of both conventional and plasmacytoid
murine DCs.
Human pDCs respond to stimulation with calcitriol
Our data show that murine pDCs exhibit impaired T-cell
stimulatory capacities upon pre-treatment with VDR ligands.
To extrapolate these findings to men, we assessed the activity
of VDR in human pDCs (hPDC). Freshly isolated pDCs from
human buffy coats expressed high levels of VDR protein
(Figure 5a). Moreover, in line with the murine data, both
human monocyte-derived DCs (moDCs) and hPDCs expressed
considerable mRNA levels of the VitD-metabolizing enzymes
Cyp27A1, Cyp2R1, and Cyp27B1 (Figure 5b).
To address the functionality of VDR, moDCs and
hPDCs were stimulated with either calcifediol alone or the
combination of calcitriol and calcifediol. Subsequently,
mRNA levels of the VDR target gene Cyp24A1 were mea-
sured. mRNA levels of Cyp24A1 were significantly induced in
moDCs and hPDCs upon stimulation with calcitriol/calcifediol
(Figure 5c). Treatment with calcifediol alone led to significant
expression of Cyp24A1 in moDCs after 16 hours, indicating
that the cells metabolize the precursor. hPDCs did not express
Cyp24A1 when stimulated with calcifediol alone (data not
shown).
These data show that human moDCs and PDCs express a
functionally active VDR.
VitD-stimulated human pDCs have impaired T-cell stimulatory
capacities
As VDR was transcriptionally active in hPDCs, we next looked
at the effect of VDR ligand stimulation on their T-cell–
activating capacity. hPDCs were prestimulated with calcife-
diol and calcitriol; subsequently, CpG was either added or not
added. hPDCs were washed extensively and incubated with
allogeneic peripheral blood leukocytes for different days. In
line with the murine pDCs, also human PDCs were markedly
impaired in their ability to induce T-cell proliferation when
pre-treated with calcitriol/calcifediol, both without stimulation
and upon CpG activation (Figure 6a).
Moreover, also production of the Th1 cytokine IFNg was
significantly decreased when hPDCs were stimulated with
VDR ligands (Figure 6b).
These data indicate that VitD is able to modulate the
function of hPDCs and acts to decrease their capacity to
induce T-cell activation.
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Figure 1. Murine plasmacyoid dendritic cells (pDCs) express vitamin D receptor (VDR) in vitro and ex vivo. (a) DCs were generated in vitro from murine bone
marrow (BM) or freshly isolated from BM and spleen. Cells were sorted into pDC and conventional DC (cDC) fractions by magnetic activated cell sorting. Murine
VDR (mVDR). VDR mRNA was detected by quantitative PCR, and mRNA levels are shown relative to the expression of mouse PBGD. VDR protein expression was
detected by (b) western blot and (c) intracellular antibody staining and subsequent FACS on in vitro–cultured pDCs and cDCs or primary cells from BM and spleen.
Geometric mean fluorescence intensities (gMFI) shown are corrected for isotype control staining. Data shown are mean values (a) or representative (b, c) of at least
three independent experiments. *Po0.05. Data are shown as mean±SEM.
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DISCUSSION
Topical application of the VitD analog calcipotriol is a highly
effective standard treatment of psoriatic skin lesions
(Tremezaygues and Reichrath, 2011). However, the
underlying mechanisms of action are still incompletely
understood. Psoriasis is an immune-driven disease and VitD
is thought to modulate inflammation in diseased skin
(Reichrath et al., 1997). Within the immune system, VitD
has pronounced tolerogenic effects on T cells and cDCs
(Adorini, 2003; Ferreira et al., 2011; Kongsbak et al., 2013).
pDCs rapidly infiltrate psoriatic skin and are at the initiation of
disease pathogenesis (Nestle et al., 2005). Here, we show that
the VDR is active in and potently inhibits murine and human
pDCs in their ability to induce T-cell proliferation and
activation.
pDCs expressed various proteins of the VDR pathway,
including the coactivator Drip205, the co-inhibitor Hairless,
and the VitD-metabolizing enzymes Cyp27A1, Cyp27B1, and
Cyp24A1. VDR was transcriptionally active in pDCs, as
shown by induced target gene expression after stimulation
with VDR ligands. Moreover, murine pDCs that were treated
with calcitriol/calcifediol before and during activation with the
Toll-like receptor 9 ligand CpG were clearly reduced in their
capacity to stimulate T-cell proliferation. Production of the
Th1 cytokine IFNg in the allogeneic mixed leukocyte reaction
was also significantly reduced by VitD pre-treatment of pDCs
and cDCs, whereas secretion of the T-cell cytokines IL5, IL17,
and IL10 was unaffected (data not shown). VitD-stimulated
DCs were previously shown to induce the generation of
tolerogenic T cells (Berer et al., 2000; Adorini, 2003;
Nikolic and Roep, 2013). However, most of these studies
have been performed with VitD treatment during the
differentiation of monocytes toward DCs. These experiments
also showed marked reduction in the expression of CD80,
CD86, and diminished secretion of proinflammatory cytokines
IL6 and IL12. We could not detect a significant inhibition of
these costimulatory molecules and cytokines in pDCs and
cDCs stimulated with VitD during maturation. The inhibitory
mechanisms of VitD during DC differentiation therefore are
likely to follow different kinetics compared with the inhibitory
mechanisms during DC maturation.
The impairment of allogeneic T-cell activation was most
pronounced in unstimulated pDCs and less in CpG-treated
cells. In addition, strong activation of murine pDCs and
cDCs with the Toll-like receptor 7/8 ligand R848 was not
affected by stimulation with VitD. Consequently, VitD-
mediated suppression of T-cell priming seems to be an
immune regulatory mechanism that is most important
during mild infections and that can be overcome by strong
immune stimuli. VitD metabolism is a multistep process
initiated in the skin with the photoinduced conversion of 7-
dehydrocholesterol and resulting in the production of the
active ligand calcitriol. Recent studies report an alternative
VitD activation pathway that is dependent on Cyp11A1.
This pathway comprises a range of bioactive VitD deriva-
tives with potential therapeutic interest owing to their low
calcemic activity (Janjetovic et al., 2009, 2010; Slominski
et al., 2012). The skin is a part of the first line of defense that
harbors various DCs (Teunissen et al., 2012; Yanofsky et al.,
2013). In this context, VDR ligands can act as a steady-state
regulatory system that may prevent autoimmune responses
while allowing immune activation toward severe
pathogenic manifestations. This hypothesis is supported by
the evident epidemiologic correlation of VitD deficiency
with psoriasis (Ricceri et al., 2013) and other autoimmune
disorders such as systemic lupus erythematosus (Kamen and
Aranow, 2008; Sakthiswary and Raymond, 2013).
Moreover, rapid skin infiltrations of pDCs are causally
linked to the early pathogenesis of psoriasis (Wollenberg
et al., 2002) and systemic lupus erythematosus (Baccala
et al., 2013).
In man, VitD is known to inhibit the differentiation and
maturation of moDCs (Piemonti et al., 2000). Moreover,
Penna et al. (2007) reported that calcitriol inhibits the
maturation of human circulating cDCs, whereas hPDCs
were not affected. In line with this, we also observed that
stimulation of hPDCs with calcitriol did not impair the
production of IFNa (data not shown), nor the expression of
CD80, CD86, major histocompatibility complex-II, and ILT3
(Supplementary Figure 3 online). However, stimulation with
VitD clearly impaired the ability of hPDCs to induce T-cell
proliferation and secretion of the Th1 cytokine IFNg.
The tolerogenic agent VitD has been studied and exploited
for the treatment of psoriasis and other cutaneous diseases
(Wollenberg et al., 2002), but the underlying molecular
mechanisms are only partly understood. Recent data
demonstrate that VitD analogs alter the expression of
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Figure 2. Murine plasmacyoid dendritic cells (pDCs) and conventional DCs
(cDCs) react to stimulation with calcitriol and its precursor calcifediol. pDCs
and cDCs were sorted from Flt3L bone marrow cultures. Expression of (a) the
co-regulators Drip205 and Hairless, (b) the vitamin D–metabolizing enzymes
Cyp27A1, Cyp2R1, and Cyp27B1, and the vitamin D receptor (VDR) target
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PBGD. Data shown are mean values of at least three independent experiments.
*Po0.05; **Po0.01. Data are shown as mean±SEM.
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antimicrobial alarmins, i.e., decreased HBD2, HBD3, and
increased cathelicidin, in psoriatic skin (Peric et al., 2009).
Interestingly, the cathelicidin peptide LL-37 has been shown to
induce pDC activation when complexed with self-DNA,
suggesting increased inflammatory responses upon VitD
treatment (Lande et al., 2007). However, VitD analogs did
not result in increased IFNa levels in psoriatic skin. The
diverse functions of LL-37 in psoriasis are still incompletely
understood, and future studies will further clarify its seemingly
paradoxical effects.
pDCs are important factors within the immune system;
although they are absent in the skin during steady state, they
rapidly infiltrate upon skin injury and during pathologic skin
conditions (Wollenberg et al., 2002). We now demonstrate
that VitD potently inhibits the ability of pDCs to induce T-cell
activation in mouse and man. Exploitation of the tolerogenic
properties of pDCs in therapeutic applications may therefore
benefit from the clinical applicability of VitD for psoriasis and
other skin pathologies.
MATERIALS AND METHODS
Mice
C57BL/6n and Balb/C mice (6–12 weeks old; Charles River Wiga,
Sulzfeld, Germany) were maintained in individually ventilated cage
units at the Central Animal Laboratory (Nijmegen, The Netherlands).
Drinking water and standard laboratory food pellets were provided
ad libitum. Experiments were performed according to the guidelines
for animal care of the Nijmegen Animal Experiments Committee.
Leuven Vdr KO mice were described elsewhere (Van Cromphaut
et al., 2001; Lieben et al., 2012). The animals were bred in the animal
housing facilities of the Proefdierencentrum Katholieke Universiteit
Leuven, received a normal diet (1.1% calcium, 0.8% phosphorus, 0%
lactose (Standard; Carfil, Oud-Turnhout, Belgium), and had free
access to tap water. The Animal Ethics Board of the KUL approved
all experimental procedures.
Murine pDCs and cDCs
DCs were generated from murine bone marrow isolated from femur/
tibia. Cells were cultured at a density of 1.5–2*10e6 ml–1 for 8–10
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Figure 3. Vitamin D–stimulated murine plasmacyoid dendritic cells (pDCs) and conventional DCs (cDCs) induce markedly impaired T-cell proliferation.
(a) pDCs and (b) cDCs were sorted from Flt3L BM cultures of either wild-type (WT) or vitamin D receptor deficient (VDR / ) mice. Purified pDCs and
cDCs were prestimulated for 2 hours with 100 nM calcitriol and 100 nM calcifediol. Subsequently, cells were stimulated again with 100 nM calcitriol, 100 nM
calcifediol, and vehicle (no stim) or 100 ng ml–1 CpG for an additional 16 hours. Cells were washed and co-incubated with carboxyfluorescein diacetate
succinimidyl ester (CFSE)-labeled splenocytes (CD11c, B220 depleted) for 5 and 6 days. T-cell proliferation was measured as indicated by CFSE dilution. Numbers
indicate the percentage of proliferation. Data shown are representative of at least three independent experiments.
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days (37 1C, 10% CO2) in RPMI 1640þ 10% fetal calf serum (Gibco-
BRL Life Technologies, Breda, The Netherlands), 0.5% antibiotic–
antimycotic (Gibco/Invitrogen, Breda, The Netherlands), 1% ultra-
glutamine (Lonza, Verviers, Belgium), 50 mM b-ME (Sigma-Aldrich,
St Louis, MO), and 200 ng ml–1 human rFlt3L (Preprotech, London,
UK). Before magentic activated cell sorting, cells were harvested and
subjected to density gradient centrifugation (PAA, Co¨lbe, Germany) to
remove dead cells.
To increase pDC and cDC counts in murine lymphoid organs, mice
were injected subcutaneously on their left flank (height of spleen)
with 5–7.5*10e6 B16Flt3L tumor cells (Nierkens et al., 2011). Tumors
were grown for 10–14 days and lymphoid organs were harvested
subsequently.
Single-cell suspensions were labeled with anti-SiglecH-FITC (eBio-
sciences, Vienna, Austria) and anti-CD11c-APC (Biolegend, ITK
Diagnostics b.v., Uithoorn, The Netherlands) antibodies for pDCs
and cDCs, respectively. pDCs were positively sorted with anti-FITC
microbeads. The negative fraction was subjected to positive selection
with anti-antigen-presenting cell microbeads (both Miltenyi Biotec,
Bergisch-Gladbach, Germany) to obtain cDCs.
Human moDCs and pDCs
DCs were isolated from buffy coats obtained from healthy volunteers
after written informed consent as per the Declaration of Helsinki and
according to institutional guidelines. Peripheral blood mononuclear
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cells were purified from buffy coats via ficoll density gradient
centrifugation (Lucron Bioproducts, Gennep, The Netherlands).
moDCs were cultured as described previously (Hontelez et al.,
2013). Plastic-adherent monocytes were cultured for 6 d in RPMI
1640 medium (Life Technologies, Breda, The Netherlands) with 1%
ultra-glutamine (PAA), 0.5% antibiotic–antimycotic (PAA), 10% (v/v)
fetal calf serum (Greiner Bio-one, Alphen a/d Rijn, The Netherlands),
IL-4 (300 U ml–1), and GM-CSF (450 U ml–1) (both Cellgenix). IL4 and
GM-CSF were added again at day 3.
pDCs were purified from peripheral blood leukocytes (nonadherent
fraction) by positive selection using anti-BDCA-4–conjugated mag-
netic microbeads (Miltenyi Biotec). As previously described, pDC
purity was assessed by double staining BDCA2/CD123 for pDCs
(495%; all Miltenyi Biotec; Tel et al., 2011). pDCs were cultured in
X-VIVO-15 medium (Lonza) with 2% human serum. 10 ng ml–1
human rIL3 (Cellgenix, Freiburg, Germany) was added if indicated.
Flow cytometry
VDR protein was detected by intracellular antibody staining.
Briefly, cells were stained with fixable viability dye efluor780
(eBioscience). Subsequently, murine organ suspensions and
human pDCs were stained for appropriate membrane markers
(see below). Cells were fixed/permeabilized with Cytofix/Cytoperm
Kit (BD Biosciences, San Jose, CA) and blocked with 1% normal goat
serum for mouse and 1% human serum for human cells. VDR was
stained and samples were acquired on a CyAn ADP Analyzer
(Beckman Coulter, Mijdrecht, The Netherlands). Data were analyzed
with the FlowJo software (TreeStar, Ashland, OR).
The following antibodies and isotype controls were used: (1)
murine: rat-anti-CD11b-PE, rat-anti-B220-PerCP, hamster-anti-
CD11c-APC, ratIgG2a-PerCp (all from Biolegend), rat-anti-PDCA1-
PE, hamster IgG1-APC (all BD Biosciences), rat IgG2b-PE, rat IgG2b-
FITC, and rat-anti-SiglecH-FITC (all from eBioscience); (2) human:
mouse-anti-BDCA2-FITC, mouse-anti-CD123-APC (both Miltenyi
Biotec), mIgG1-FITC, and mIgG1-APC (eBioscience).
For murine and human samples, VDR was detected with
either m-anti-VDR or m-anti-VDR-biotin at 4mg ml–1 (both clone
D6, Santa Cruz Biotechnology, Heidelberg, Germany) and secondary
detection antibodies goat-anti-mIg-PE or streptavidin-PE (both BD
Biosciences), respectively.
RNA isolation, reverse transcriptase–PCR, and quantitative PCR
Total RNA was isolated with the RNeasy MiniPrep Kit (Qiagen
Benelux, Venlo, The Netherlands) or Quick-RNA MiniPrep
(ZymoResearch, Base Clear lab products, Leiden, The Netherlands)
according to the manufacturer’s instructions. RNA was transcribed
into complementary DNA with the RT2 First Strand cDNA Kit
(SABiosciences, Qiagen Benelux, Venlo, The Netherlands). Alterna-
tively, RNA was treated with DNase I (amplification grade; Invitrogen,
Breda, The Netherlands) and reverse-transcribed into complementary
DNA using random hexamers and moloney murine leukemia virus
reverse transcriptase (Invitrogen). mRNA levels of genes of interest
(see Supplementary Table 1 online) were detected by quantitative
PCR with FastStart SYBR Green Master (Roche Applied Science,
Almere, The Netherlands). Samples were read on a CFX96 Real Time
System (Bio-Rad, Veenendaal, The Netherlands). mRNA levels were
normalized to the housekeeping gene PBGD and are expressed as
2 (Ct gene of interest minus Ct PBGD).
Western blotting
In all, 5*10e6 murine in vitro–derived cDCs and pDCs were lysed
in 1% SDS and 62.5 mM Tris, pH 6.8. Cell lysates were mixed with
sample buffer (5% glycerol, 6% SDS, 125 mM Tris-HCL, pH 6.8,
0.1 mg ml–1 bromophenol blue, and 10% b-ME), heated to 95 1C for
5 min, resolved by 10% SDS-PAGE, and transferred to nitrocellu-
lose membranes (4 1C, 30 mA) (Schleicher and Schuell, Meppel,
The Netherlands). Membranes were blocked with 3% BSA and 1%
milk powder in phosphate buffered saline + 0.1% tween-20 (PBST)
(1 hour room temperature) and subsequently stained with 1 mg ml–1
m-anti-VDR (clone D6, Santa Cruz Biotechnology) and rb-anti-actin
(Sigma-Aldrich) (both in 14 PBST, 1 hour room temperature). After
washing three times with PBST secondary Abs, goat-anti-mouse
IRDye 800CW and donkey-anti-rabbit IRDye 680RD (Li-cor Bios-
ciences) were added (14 PBST, 1 hour room temperature). Mem-
branes were washed three times in PBST and scanned with an
Odyssey Infrared Imaging System (Li-cor Biosciences, Lincoln, NE)
to visualize proteins.
Stimulation experiments DCs
Human and murine DC subsets were cultured at a concentration of
1*10e6 cells ml–1. For target gene detection, cells were stimulated
with 100 nM calcitriol (1,25-(OH)2D3), 100 nM calcifediol
(25(OH)D3) (both Sigma-Aldrich), a combination of both, or vehicle
(EtOH). For the FACS staining of costimulatory molecules, human
pDCs were prestimulated with 100 nM 1,25(OH)2D3 and 100 nM
25(OH)D3 for 2 hours, and subsequently VitD derivatives and 0.5mg
ml–1 ODN-CpG C (M362; Axxora, San Diego, CA) were added for
additional incubation overnight.
Mixed leukocyte reaction murine DCs
Isolated pDCs and cDCs were prestimulated with vehicle or 100 nM
calcifediol and 100 nM calcitrol for 2 hours. Subsequently, additional
VitD derivatives and 0.1mg ml–1 CpGB (1668, Sigma-Aldrich) or
0.4mg ml–1 Resiquimod (R848, Axxora) were added for additional
incubation O/N. Supernatant was collected, DCs were washed with
phosphate-buffered saline, and 504 carboxyfluorescein diacetate
succinimidyl ester–labeled allogeneic splenocytes (depleted for
CD11c and B220) were added in a ratio of 1:2 and 1:6. Cells were
incubated in round-bottom 96-well cluster plates (Corning, Amsterdam,
The Netherlands).
Mixed leukocyte reaction human DCs
Isolated pDCs were prestimulated with vehicle or 100 nM calcifediol
and 100 nM calcitrol for 2 hours. Subsequently, additional VitD
derivatives and 0.5mg ml–1 CpG-C ODN were added and cells were
incubated for an additional 5 hours. Supernatant was collected, pDCs
were washed with phosphate-buffered saline, and 105 carboxyfluor-
escein diacetate succinimidyl ester–labeled allogeneic peripheral
blood leukocytes were added in a ratio of 1:17. Cells were incubated
for the indicated times in round-bottom 96-well cluster plates
(Corning).
ELISA
Human IFNg levels were measured with the ELISA Ready-SET-
Go!RSG kit according to the manufacturer’s instructions
(eBioscience). Murine IFNg levels were measured by sandwich ELISA
with rat-anti-mIFNgamma (clone R4-6A2, BD), anti-mIFNgamma-
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biotin (clone XMG 1.2, Biolegend), streptavidin-horseradish perox-
idase (Invitrogen), and 3,30,5,50-tetramethylbenzidine (Sigma-Aldrich)
substrate.
Statistics
Data were analyzed with one- or two-tailed, Student’s t-test
using GraphPad Prism 5.0 (La Jolla, CA). *Po0.05; **Po0.01;
***Po0.001.
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